Melanoma Clinical Trial
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Summary
The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
Eligibility Criteria
Inclusion Criteria:
Male or female, age 40 - 75 years old
Diagnosis of cancer
Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or not receiving any treatment.
Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤2 antihypertensive medications
Exclusion Criteria:
Presence of peripheral artery disease
History of a heart attack within 1 year
History of a stroke within 1 year
Diabetes
Life expectancy < 3 months
Women who are pregnant
Women who are nursing
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Nashville Tennessee, 37232, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.